BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ZS Pharma Lands $46 Million for Kidney and Liver Drug Development


10/24/2012 7:26:40 AM

Dallas Business Journal by Bill Hethcock, Staff Writer

Specialty pharmaceutical company ZS Pharma Inc. has raised $46 million to advance development of ZS-9, a crystal form of zirconium silicate, designed to treat patients with kidney and liver disease.

The funding will allow the privately held Fort Worth company to proceed with trials for ZS-9 as it prepares for commercialization of the product.

Alta Partners led the new round of financing, joined by new investors RiverVest Venture Partners, 3x5 Special Opportunity Partners and Salem Partners, and by current investor Devon Park Bioventures.

ZS Pharma has developed a compound that selectively removes life-threatening toxins from patients suffering from kidney and liver disease and related conditions. Initial human clinical testing focused on patients with hyperkalemia, or elevated levels of potassium in their blood.

“We are very excited to partner with our new investors to further develop novel treatments for hyperkalemia and other unmet medical needs,” said Al Guillem, ZS Pharma’s president and CEO.

Darlene M. Ryan, executive director of the a nonprofit business incubator TECH Fort Worth, called it “a thrill” to work with ZS Pharma. She said it’s the biggest round of funding a company hatched in the incubator has ever landed.

“Venture capitalists do not invest $46 million without believing in this drug and in this team,” Ryan said.

As part of this deal, Robert Alexander, general partner of Alta Partners, and John McKearn, managing partner of RiverVest Venture Partners, will join the ZS Pharma Board of Directors.

ZS Pharma, founded in 2008, has further plans to research and develop other compounds targeting kidney and liver disease — conditions with limited treatment options today.




 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES